查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年口腔液快速筛查设备的全球市场
市场调查报告书
商品编码
1217600

2022-2029 年口腔液快速筛查设备的全球市场

Global Rapid Oral Fluid Screening Device Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

口腔液筛查正变得越来越流行，因为它是一种无创且可直接观察的样本采集方法。 口腔液筛查是比尿液分析更好的功能障碍指标，因为它具有更短的检测週期并且与血液药物浓度的相关性更强。

市场动态

口腔液体快速筛查设备的全球市场受到口腔疾病患病率上升、技术进步、医疗设备研发、先进医疗技术的采用、患者对快速药物筛查意识的提高以及医疗成本降低的推动。增长带动。

药物滥用和酒精中毒增加导致市场扩张

在预测期内，年轻人对药物检测和酒精中毒的需求不断增长，将推动市场发展。 根据 2022 年发表在《科学报告》(Scientific Reports) 上的一篇文章，年轻人经常光顾酒吧、俱乐部和节日等各种夜生活场所并进行社交活动。 研究表明，精神活性物质的使用在这些环境中尤为普遍。 研究表明，非法药物使用与大量饮酒有关。 酒精和非法药物的使用会导致严重的暴力后果（包括性侵犯）、事故和死亡。 经常使用这些物质会增加患物质使用障碍等身心疾病的风险。

此外，还在澳大利亚俱乐部参与者中进行了口腔液样本的快速现场免疫筛查测试，表明 9% 的人报告吸毒，20% 的人检测呈阳性。我来了。 口腔液取样是一种非侵入性方法，与血液取样获得的结果一致，但取样对一些参与者来说可能很耗时，而且通常是由多种药物或药剂引起的。 口干。

对口腔液检测的好处和应用的认识和理解有限阻碍了市场增长

但是，有几个因素可能会抑制口腔液筛查设备市场的快速增长。 这些可能包括对口腔液测试的好处和用途的认识和理解有限。 对口腔液检测的好处和应用的认识和理解有限可能是口腔液快速筛查设备市场增长的限制因素。 由于口腔液检测是一个相对较新且发展中的领域，许多人可能需要更好地了解它并了解其潜在用途。 因此，他们可能不太可能使用口腔液筛查设备或寻求口腔液检测服务。 特别是，这种现象可能发生在需要熟悉先进医疗技术和习惯于诊断测试的人群中。

但是，随着有关口腔液检测的信息越来越多，并且越来越多的人意识到它的好处和用途，对口腔液快速筛查设备的需求可能会增加。 这可能会推动这些设备的市场增长。

COVID-19 影响分析

COVID-19 的出现对全球口腔液筛查设备市场产生了相当大的影响。 根据 2021 年发表在《临床微生物学杂誌》上的一篇文章，对可大规模生产以进行广泛测试并可维持 FDA 推荐的测试规范的非侵入性 SARS-CoV-2 抗体测试的需求导致了 OraSure It导致与技术合作。 OraSure Technologies 的口腔标本采集设备 (OSCD) 已经建立，用于采集和储存针对人类免疫缺陷病毒 1 型 (HIV-1) 的口腔液抗体。 该公司的口服抗体收集装置 (OACD) 经过改进，可用于收集针对 SARS-CoV-2 的抗体，使用含有盐和柠檬酸的吸水垫收集牙龈和脸颊之间的口腔液。 口腔的这一部分含有富含抗体的龈沟液。 因此，在 OACD 中，通过从该部位采集样本，可以获得比单独的唾液更富含抗体的口腔液样本。

内容

第 1 章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 吸毒和酗酒现象增多
      • 更严格的药物和酒精检测法规和义务
      • 工作场所筛查在城市地区的重要性与日俱增
    • 约束因素
      • 对先进的快速唾液筛查设备的可用性缺乏认识
    • 商机
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • 1 面板式唾液药物检测套件
  • 4 面板型唾液药物检测套件
  • 5 联式唾液药物检测试剂盒
  • 6 联式唾液药物检测试剂盒
  • 10 联式唾液药物检测试剂盒
  • 12 联唾液药物检测试剂盒

第八章形态学

  • 磁带
  • 棉籤
  • 脱衣舞

第9章应用

  • 刑事司法考试
  • 工作场所检查
  • 疾病检测

第 10 章最终用户

  • 医院
  • 诊断机构
  • 法医研究所
  • 独资企业
  • 家庭医疗

第11章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第12章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 按类型划分的基准

第13章公司简介

  • OraSure Technologies, Inc.
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Abbott Laboratories
  • Guangzhou Wondfo Biotech Co., Ltd
  • Oranoxis Inc
  • Premier Biotech, Inc
  • UCP Biosciences, Inc.
  • SCREEN ITALIA SRL
  • Securetec Detektions-Systeme AG
  • MEDACX Ltd.
  • AccuBioTech Co. Ltd

第14章 DataM

简介目录
Product Code: DMMD1445

Market Overview

The global rapid oral fluid screening device market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Oral fluid screening is increasingly popular as it is a non-invasive and directly observable sample collection method. Oral fluid screening is a better indicator of impairment as it has a shorter detection window and a stronger correlation with blood drug concentrations than urine testing.

Market Dynamics

The global rapid oral fluid screening device market is driven by the rising prevalence of oral disorders, technological advancements, research and development in medical devices, adoption of advanced healthcare technologies, improving patient awareness about rapid drug screening, and rising healthcare expenditure.

Increasing cases of drug abuse and alcoholism drives market growth

The rising demand for testing drugs and alcoholism in young adults drive the market in the forecast period. As per the article published in Scientific Reports in 2022, young adults frequently visit and socialize in different nightlife venues such as bars, clubs, and festivals. Studies have shown that psychoactive substance use is especially high in these environments. Research indicates that illicit drug use is associated with high levels of alcohol consumption. The use of alcohol and illicit drugs can lead to serious acute consequences such as violence (including sexual assault), accidents, and even death. Frequent use of these substances increases the risk of physical and mental illnesses, including substance use disorders.

In addition, an on-site immunological quick screening test of oral fluid samples has also been conducted among Australian clubgoers, demonstrating that 9% had reported drug use and 20% tested positive. Although oral fluid sampling is a non-invasive method, which agrees with the results obtained from blood sampling, sampling can be time-consuming in some participants, often due to a dry mouth, which some drugs or medications can induce.

Limited awareness and understanding about the benefits and uses of oral fluid testing will hamper the growth of the market

However, several factors could restrain the growth of the rapid oral fluid screening device market. These may include limited awareness and understanding of the benefits and uses of oral fluid testing. Limited awareness and understanding of the benefits and uses of oral fluid testing can be a factor that restrains the growth of the rapid oral fluid screening device market. Oral fluid testing is a relatively new and evolving field, and many people may need to be more familiar with it or aware of its potential applications. Resulting, they may be less likely to use oral fluid screening devices or seek out oral fluid testing services. This can be especially true in segments of the population that may need to become more familiar with advanced medical technologies or more accustomed to using diagnostic testing.

However, as more information about oral fluid testing becomes available and more people become aware of its benefits and uses, the demand for rapid oral fluid screening devices will likely increase. This could drive growth in the market for these devices.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global oral fluid screening device market. As per the article published in the Journal of Clinical Microbiology in 2021, the need for a noninvasive SARS-CoV-2 antibody test that could be mass-produced for widespread testing and maintain testing specifications recommended by the FDA led to a collaboration with OraSure Technologies. The ability of OraSure Technologies' oral specimen collection device (OSCD) to gather and preserve oral fluid antibodies against human immunodeficiency virus type 1 has previously been established (HIV-1). Their oral antibody collection device (OACD), modified for better antibody collection for antibodies against SARS-CoV-2, uses an absorbent pad containing salts and citric acid to collect oral fluid between the gums and cheeks. An antibody-rich gingival crevicular fluid is present in this area of the mouth. Therefore, by taking samples from this area, the OACD obtains oral fluid samples that are more abundant in antibodies than saliva alone.

Segment Analysis

The disease testing segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The disease testing segment accounts for the largest market share. During COVID-19, clinical and healthcare demands have been on the rapid rise. Major challenges during the pandemic have included a lack of testing kits, shortages of ventilators to treat severe cases of COVID-19, and insufficient access to personal protective equipment for hospitals and the public. Scientists, researchers, and companies have developed new technologies, including rapid oral fluid screening devices, in response to these demands-increasing demand for disease testing by using rapid oral fluid screening for diagnosis.

In addition, VerOFy & LIAM Rapid Saliva Point-of-Care Testing offers VerOFy a unique platform technology that combines rapid and standardized saliva [oral fluid] collection with high-quality immunochromatographic test strips for delivery of immediate results in the field or point-of-care locations.

Geographical Analysis

North America region holds the largest market share of the global rapid oral fluid screening device market

North America dominates the market for rapid oral fluid screening devices and is anticipated to show a similar trend over the forecast period. There are several reasons why the North American region may dominate the rapid oral fluid screening market globally. Strong healthcare infrastructure and advanced medical technologies in the region have contributed to the high adoption rate of oral fluid screening devices. The region's high prevalence of substance abuse and addiction has led to a strong demand for reliable and accurate testing methods. The availability of a wide range of rapid oral fluid screening devices in the North American market offers consumers various options-a favorable regulatory environment for the region's approval and marketing of oral fluid screening devices. High levels of healthcare spending in the North American region have helped fuel the growth of the rapid oral fluid screening market.

In addition, OraSure Technologies offers Intercept i2 Oral Fluid Collection Device that provides a 3-minute collection time (average) with a patented treated pad, no pre-collection sample pooling required, and an ergonomic collector designed for a comfortable end-user experience.

Competitive Landscape

The rapid oral fluid screening device market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are OraSure Technologies, Inc, Abbott Laboratories, Guangzhou Wondfo Biotech Co., Ltd, Oranoxis Inc, Premier Biotech, Inc, UCP Biosciences, Inc., SCREEN ITALIA SRL, Securetec Detektions-Systeme AG, MEDACX Ltd., and AccuBioTech Co. Ltd, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the rapid oral fluid screening device market globally.

For instance,

  • In April 2020, OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analytical services, was awarded a $710,310 contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS), to design a pan-SARS-coronavirus antigen rapid in-home self-test that uses oral fluid samples. This support from BARDA will enable OraSure to file for FDA Emergency Use Authorization (EUA), allowing an in-home self-test to debut in the U.S. market.

Abbott Laboratories

Overview:

Abbott Laboratories is a healthcare and medical device organization founded in 1888 and headquartered in the United States. For over 130 years, the company put science and innovation to work - to develop more opportunities for more people through the power of health.

Product Portfolio:

OrALert ORAL FLUID DRUG SCREEN DEVICE: The OrALert Oral Fluid Drug Screen Device is easy, quick, and provides results in under 10 minutes. Benefits include Available tests including mAMP OPI, AMP, BZO, COC, PCP and THC1, improved detection of parent THC, reliable screening for illicit and prescription drugs in saliva, minimum exposure to specimen, and split specimen well.

The global rapid oral fluid screening device market report would provide access to approximately 60+ market data tables, 60+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing cases of drug abuse and alcoholism
      • 4.1.1.2. Tougher regulations and mandates for drug and alcohol testing
      • 4.1.1.3. The growing emphasis on workplace screening among urban populations
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of awareness regarding the availability of advanced rapid saliva screening devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. 1- Panel Saliva Drug Test Kit*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. 4- Panel Saliva Drug Test Kits
  • 7.4. 5- Panel Saliva Drug Test Kits
  • 7.5. 6- Panel Saliva Drug Test Kits
  • 7.6. 10- Panel Saliva Drug Test Kits
  • 7.7. 12- Panel Saliva Drug Test Kits

8. By Form

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Form
    • 8.1.2. Market Attractiveness Index, By Form
  • 8.2. Cassettes*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Swabs
  • 8.4. Strips

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Criminal Justice Testing*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Workplace Testing
  • 9.4. Disease Testing

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Diagnostic Laboratories
  • 10.4. Forensic Laboratories
  • 10.5. Private Employers
  • 10.6. Home Care Settings

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Form
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Form
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Form
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Form
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Form
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Type Benchmarking

13. Company Profiles

  • 13.1. OraSure Technologies, Inc*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Abbott Laboratories
  • 13.3. Guangzhou Wondfo Biotech Co., Ltd
  • 13.4. Oranoxis Inc
  • 13.5. Premier Biotech, Inc
  • 13.6. UCP Biosciences, Inc.
  • 13.7. SCREEN ITALIA SRL
  • 13.8. Securetec Detektions-Systeme AG
  • 13.9. MEDACX Ltd.
  • 13.10. AccuBioTech Co. Ltd

LIST NOT EXHAUSTIVE

14. Global Rapid Oral Fluid Screening Device Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us